KPTI
HealthcareKaryopharm Therapeutics Inc.
$7.40
+$0.21 (+2.92%)
Jan 5, 2026
Price History (1Y)
Analysis
Karyopharm Therapeutics Inc. is a biotechnology company in the healthcare sector with a market capitalization of $126.18M and revenue of $142.53M (TTM). The company has 279 employees. The company's financial health is characterized by significant net losses, with a net income of -$124,621,000 (TTM) and EBITDA of -$103,786,000. Its operating margin stands at -34.6% and profit margin at -87.4%. The company has a gross margin of 104.3% but reports negative return on assets (-45.6%) due to its substantial debt. Karyopharm Therapeutics Inc. has $269.92M in debt, but also holds $45.88M in cash. Karyopharm's valuation context is marked by a forward P/E of -1.52 and an EV/EBITDA of -3.37. The company reports revenue growth of 13.6% year-over-year (YoY) but does not provide data on earnings growth due to its net losses.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $126.18M
- P/E Ratio
- N/A
- 52-Week High
- $12.15
- 52-Week Low
- $3.51
- Avg Volume
- 231.68K
- Beta
- 0.21
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 279